BeRS-GSK AWARDS 2020 - 14th October 2020 : audition of all candidates in the Cercle du Lac - Louvain-la-Neuve
Prof. Wim Janssens (President BeRS), Prof. Guy Brusselle (Scientific Secretary BeRS) and Dr. Thomas Doran, GSK Medical Director BeLux, had the pleasure to nominate the four following winners :
The Belgian Respiratory Society (BeRS) BASIC SCIENCE AWARDS – supported by GSK – have been awarded to :
1st price - 2000 € : Dr. Laura Seldeslachts (KUL) : Unravelling the pathogenic mechanism behind influenza-associated pulmonary aspergillosis
2nd price - 1500 € : Dr. Cedric Bosteels (UGent) : Prevalence and incidence of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in Flanders : a 12 years collaborative multicentre
The Belgian Respiratory Society (BeRS) CLINICAL SCIENCE AWARDS – supported by GSK – have been awarded to two clinicians who presented excellent, investigator-initiated, prospective clinical research with important key messages for clinical practice.
1st price - 2000 € : Dr. Tatjana Decaesteker (KUL) demonstrated that a cold air exercise test (CAET) induces acute bronchoconstriction not only in mild asthmatic patients, but also in healthy controls who had a normal spirometry but a positive histamine provocation test. In asthmatics, the acute bronchoconstriction upon CAET was associated with systemic and airway neutrophilia, and increased pro-inflammatory cytokine levels in sputum. Intriguingly, in healthy subjects, airway hyperreactivity to histamine and CAET was associated with prior exposure to fine particulate matter (PM10).
2nd price - 1500 € : Dr. Koen Verbeke (UGent) presented the results of a prospective longitudinal cohort study of 722 consecutive patients with systemic sclerosis (SSc) with up to 12 years of follow-up (mainly at Ghent University Hospital). Based upon lung function tests and high resolution CT scan of the thorax (HRCT), 33% of subjects with systemic sclerosis had evidence of interstitial lung disease (ILD) at baseline, of whom 60% had lung functional and 21% HRCT progression at 5 years of follow-up. Therefore, both limited cutaneous and diffuse cutaneous SSc patients should be monitored for ILD development or progression.